Drug companies forge partnerships with top schools

by Alan Scher Zagier

(AP)—Pharmaceutical companies that can no longer rely on lucrative patents to drive profits are increasingly teaming up with academia in search of the next big drug discovery.

., Astra Zeneca PLC and and Co. are among the drug makers signing seven-figure, multiyear agreements with schools such as New York University, Harvard and the University of California at San Francisco. The deals give campus scientists access to once-proprietary experimental owned by the corporate labs.

Big Pharma has long sought to profit from campus research. But rather than focus on specific projects, the two sides are now joining forces in unprecedented ways—often as equal partners.

Most rely on "template" agreements that spell out intellectual property and other legal issues.

3 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Pharmaceutical intellectual property laws need reform

Nov 07, 2011

Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation in developing new drugs, states an analysis in CMAJ (Canadian Medical Association Journal).

Big Pharma cashes in on HGH abuse

Dec 21, 2012

An Associated Press investigation shows that a federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's ...

Bayer 'disappointed' after losing India patent fight

Sep 26, 2012

Pharmaceutical giant Bayer AG on Wednesday said it was "disappointed" with an Indian ruling that allows a local firm to produce a cheaper copy of its patented drug Nexavar for liver and lung cancer.

Bayer challenges India cancer drug ruling

May 06, 2012

German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.